Granted Patent
B2
US 12,492,260 · App. 18/600,484 · Granted Dec 9, 2025
Antibodies that bind to IL1RAP and uses thereof
Inventors:
Julie Macoin (La Chaux-de-Fonds, CH); Amelie Croset (La Chaux-de-Fonds, CH); Jeremy Loyau (La Chaux-de-Fonds, CH); Thierry Monney (La Chaux-de-Fonds, CH); Lamine Mbow (La Chaux-de-Fonds, CH); Marie-Agnes Doucey (La Chaux-de-Fonds, CH); Valentina Labanca (La Chaux-de-Fonds, CH)
Assignee:
IGI THERAPEUTICS SA
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
Claims (12)
1 . An anti-interleukin-1 receptor accessory protein (IL1RAP) antibody comprising a first heavy chain CDR region (CDR-H1), a second heavy chain CDR region (CDR-H2), and a third heavy chain CDR region (CDR-H3), wherein:
(a) the CDR-HI comprises the amino acid sequence of SEQ ID NO: 87;
(b) the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 147; and
(c) the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 207,
and
wherein said anti-IL1RAP antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 268.
2 . The antibody of claim 1 , wherein said antibody binds to human IL1RAP with a binding affinity of 1×10 −8 M or less.
3 . The antibody of claim 2 , wherein the binding affinity to human IL1RAP polypeptide of SEQ ID NO: 1 or 6 is measured by equilibrium dissociation constant (KD).
4 . The antibody of claim 1 , wherein said antibody cross-reacts with a cynomolgus monkey IL1RAP polypeptide of SEQ ID NO: 2.
5 . The antibody of claim 1 , wherein said antibody is a full-length antibody of class IgG, and wherein the class IgG antibody has an isotype selected from IgG1, IgG2, IgG3, and IgG4.
6 . The antibody of claim 1 , wherein said antibody is a multispecific antibody.
7 . A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
Assignments (2)
CHANGE OF NAME
Recorded Aug 25, 2025
From: ICHNOS SCIENCES SA
To: IGI THERAPEUTICS SA
Reel/Frame 072111/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 8, 2024
From: MACOIN, JULIE; CROSET, AMELIE; LOYAU, JEREMY; MONNEY, THIERRY; MBOW, LAMINE; DOUCEY, MARIE-AGNES; LABANCA, VALENTINA
To: ICHNOS SCIENCES SA
Reel/Frame 067923/0527 →
Priority Claims (4)
EP 20195961
· Sep 14, 2020
· regional
EP 21151218
· Jan 12, 2021
· regional
EP 21159485
· Feb 26, 2021
· regional
EP 21179711
· Jun 16, 2021
· regional
Continuity (2)
References Cited (220)
US 4676980A
· Segal et al.
· 1987
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5571894A
· Wels et al.
· 1996
[cited by applicant]
US 5587458A
· King et al.
· 1996
[cited by applicant]
US 5595756A
· Bally
· 1997
[cited by examiner]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5770429A
· Lonberg et al.
· 1998
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 5959177A
· Hein et al.
· 1999
[cited by applicant]
US 6040498A
· Stomp et al.
· 2000
[cited by applicant]
US 6075181A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6150584A
· Kucherlapati et al.
· 2000
[cited by applicant]
US 6171586B1
· Lam et al.
· 2001
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6248516B1
· Winter et al.
· 2001
[cited by applicant]
US 6267958B1
· Andya et al.
· 2001
[cited by applicant]
US 6420548B1
· Vezina et al.
· 2002
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 6982321B2
· Winter
· 2006
[cited by applicant]
US 7041870B2
· Tomizuka et al.
· 2006
[cited by applicant]
US 7087409B2
· Barbas et al.
· 2006
[cited by applicant]
US 7125978B1
· Vezina et al.
· 2006
[cited by applicant]
US 7189826B2
· Rodman
· 2007
[cited by applicant]
US 7332581B2
· Presta
· 2008
[cited by applicant]
US 7521541B2
· Eigenbrot et al.
· 2009
[cited by applicant]
US 7527791B2
· Adams et al.
· 2009
[cited by applicant]
US 7658921B2
· Dall'Acqua et al.
· 2010
[cited by applicant]
US 8664475B2
· Puzio et al.
· 2014
[cited by applicant]
US 20020164328A1
· Shinkawa et al.
· 2002
[cited by applicant]
US 20030115614A1
· Kanda et al.
· 2003
[cited by applicant]
US 20030157108A1
· Presta
· 2003
[cited by applicant]
US 20040093621A1
· Shitara et al.
· 2004
[cited by applicant]
US 20040109865A1
· Niwa et al.
· 2004
[cited by applicant]
US 20040110282A1
· Kanda et al.
· 2004
[cited by applicant]
US 20040110704A1
· Yamane et al.
· 2004
[cited by applicant]
US 20040132140A1
· Satoh et al.
· 2004
[cited by applicant]
US 20050014934A1
· Hinton et al.
· 2005
[cited by applicant]
US 20050260186A1
· Bookbinder et al.
· 2005
[cited by applicant]
US 20060104968A1
· Bookbinder et al.
· 2006
[cited by applicant]
US 20140079691A1
· Mcconnell
· 2014
[cited by examiner]
EP 0404097B1
· 1996
[cited by applicant]
WO WO9301161A1
· 1993
[cited by applicant]
WO WO9316185A2
· 1993
[cited by applicant]
WO WO9429351A2
· 1994
[cited by applicant]
WO WO9951642A1
· 1999
[cited by applicant]
WO WO0061739A1
· 2000
[cited by applicant]
WO WO0129246A1
· 2001
[cited by applicant]
WO WO0231140A1
· 2002
[cited by applicant]
WO WO03084570A1
· 2003
[cited by applicant]
WO WO03085107A1
· 2003
[cited by applicant]
WO WO03085119A1
· 2003
[cited by applicant]
WO WO2004056312A2
· 2004
[cited by applicant]
WO WO2005012359A2
· 2005
[cited by applicant]
WO WO2005035778A1
· 2005
[cited by applicant]
WO WO2005053742A1
· 2005
[cited by applicant]
WO WO2005063816A2
· 2005
[cited by applicant]
WO WO2005100402A1
· 2005
[cited by applicant]
WO WO2006029879A2
· 2006
[cited by applicant]
WO WO2006044908A2
· 2006
[cited by applicant]
WO WO2007048037A2
· 2007
[cited by applicant]
WO WO2007059782A1
· 2007
[cited by applicant]
WO WO2005035586A1
· 2007
[cited by applicant]
WO WO2008077546A1
· 2008
[cited by applicant]
WO WO2008145137A2
· 2008
[cited by applicant]
WO WO2008145138A1
· 2008
[cited by applicant]
WO WO2009089004A1
· 2009
[cited by applicant]
WO WO2012098407A1
· 2012
[cited by applicant]
WO WO2012131555A2
· 2012
[cited by applicant]
WO WO2014100772A1
· 2014
[cited by applicant]
WO WO2015132602A1
· 2015
[cited by examiner]
WO WO2016020502A1
· 2016
[cited by applicant]
WO WO2016207304A2
· 2016
[cited by applicant]
WO WO2017079121A2
· 2017
[cited by applicant]
WO WO2017191325A9
· 2018
[cited by applicant]
WO WO2018071910A2
· 2018
[cited by applicant]
WO WO2018231827A1
· 2018
[cited by applicant]
WO WO2019028190A1
· 2019
[cited by applicant]
WO WO2019175359A1
· 2019
[cited by applicant]
WO WO2020035577A1
· 2020
[cited by applicant]
WO WO2020037154A1
· 2020
[cited by applicant]
WO WO2022053715A1
· 2022
[cited by applicant]
Heppner et al., Tumor heterogeneity: biological implications and therapeutic consequences, 1983, Cancer Metastasis Reviews 2: 5-23 (Year: 1983).
[cited by examiner]
Lazar et al., Mol. Cell. Biol., 8:1247-1252, 1988 (Year: 1988).
[cited by examiner]
Burgess et al. Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single L…
[cited by examiner]
Jain RK, Barriers to Drug Delivery in Solid Tumors, 1994, Scientific American, pp. 58-645 (Year: 1994).
[cited by examiner]
Brown et al., J Immunol. May 1996;156(9):3285-91 (Year: 1996).
[cited by examiner]
MacCallum et al., 1996, J. Mol. Biol. 262: 732-745 (Year: 1996).
[cited by examiner]
Gura T, Systems for Identifying New Drugs are Often Faulty, Science, 1997, 278(5340): 1041-1042 (Year: 1997).
[cited by examiner]
Topp et al, Journal of Controlled Release, 1998, 53:15-23 (Year: 1998).
[cited by examiner]
Greenspan et al. 1999 Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937 (Year: 1999).
[cited by examiner]
Bork. Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research, 2000, 10:398-400 (Year: 2000).
[cited by examiner]
Skolnick et al., Trends Biotechnol. Jan. 2000;18(1):34-9 (Year: 2000).
[cited by examiner]
Sporn et al. Chemoprevention of Cancer, Carcinogenesis, vol. 21 (2000), 525-530 (Year: 2000).
[cited by examiner]
Auerbach et al, Angiogenesis assays: Problems and pitfalls, Cancer and Metastasis Reviews, 2000, 19: 167-172 (Year: 2000).
[cited by examiner]
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28 at 416 (Year: 2002).
[cited by examiner]
Paul, Fundamental Immunology, 2003, 5th Edition, Raven Press, New York, Chapter 3, pp. 109-147 (Year: 2003).
[cited by examiner]
Casset et al., 2003, Biochemical and Biophysical Research Communications 307:198-205 (Year: 2003).
[cited by examiner]
Christiansen et al, Mol Cancer Ther, 2004, 3:1493-1501 (Year: 2004).
[cited by examiner]
Hait., Anticancer drug development: the grand challenges, Nature Reviews/Drug Discovery, 2010, 9, pp. 253-254 (Year: 2010).
[cited by examiner]
Blumberg et al. (Nat Med. (2012); 18(1): 35-41) (Year: 2012).
[cited by examiner]
Gravanis et al., The changing world of cancer drug development: the regulatory bodies' perspective, Chin Clin Oncol, 2014, 3, pp. 1-5 (Year: 2014).
[cited by examiner]
Henke et al, Kidney International (2014) 86, 780-789 (Year: 2014).
[cited by examiner]
Miosge, Proc Natl Acad Sci U S A. Sep. 15, 2015;112(37):E5189-98 (Year: 2015).
[cited by examiner]
Kulmanov et al., Bioinformatics, 34(4), 2018, 660-668 (Year: 2018).
[cited by examiner]
Beans, Targeting metastasis to halt cancer's spread, PNAS 2018; 115(50): 12539-12543 (Year: 2018).
[cited by examiner]
Almagro, J. C., and Fransson, J., “Humanization of antibodies,”
[cited by applicant]
Baca, M., et al., “Antibody Humanization Using Monovalent Phage Display,”
[cited by applicant]
Binz, H. K., et al., “Engineering novel binding proteins from nonimmunoglobulin domains,”
[cited by applicant]
Boerner, P., et al., “Production of Antigen-specific Human Monoclonal Antibodies from in Vitro-primed Human Splenocytes,”
[cited by applicant]
Brennan, M., et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,”
[cited by applicant]
Brodeur, B. R., et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas,” in
[cited by applicant]
Bruggemann, M., et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,”
[cited by applicant]
Capel, P. J., et al., “Heterogeneity of human IgG Fc receptors,”
[cited by applicant]
Carter, P., et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,”
[cited by applicant]
Chothia, C., and Lesk, A. M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”
[cited by applicant]
Chothia, C., et al., “Conformations of Immunoglobulin Hypervariable Regions,”
[cited by applicant]
Chowdhury, P. S., “Engineering hot spots for affinity enhancement of antibodies,”
[cited by applicant]
Clackson, T., et al., “Making antibody fragments using phage display libraries,”
[cited by applicant]
Clynes, R., et al., “Fc receptors are required in passive and active immunity to melanoma,”
[cited by applicant]
Cragg, M. S., and Glennie, M. J., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood 103(7):2738-2743, Elsevier, United States (Apr. 2004).
[cited by applicant]
Cragg, M. S., et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,”
[cited by applicant]
Cunningham, B. C., and Wells, J. A., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis,”
[cited by applicant]
Daeron, M., “Fc receptor biology,”
[cited by applicant]
Dall'Acqua, W. F., et al., “Antibody humanization by framework shuffling,”
[cited by applicant]
Fellouse F. A., et al., “Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition,”
[cited by applicant]
Fiedler, M., and Skerra, A., “Chapter 17: Non-Antibody Scaffolds as Alternative Therapeutic Agents,” in
[cited by applicant]
Flatman, S., et al., “Process analytics for purification of monoclonal antibodies,”
[cited by applicant]
Garlanda, C., “The interleukin-1 family: back to the future,”
[cited by applicant]
Gazzano-Santoro, H., et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,”
[cited by applicant]
Gebauer, M., and Skerra, A., “Engineered protein scaffolds as next-generation antibody therapeutics,”
[cited by applicant]
GenBank, “interleukin-1 receptor accessory protein isoform X7 [Gallus gallus],” Accession No. XP_422719.4, accessed at URL:[https://www.ncbi.nlm.nih.gov/protein/XP_422719.4] on Dec. 27, 2021, 2 pages.
[cited by applicant]
Gerngross, T. U., “Advances in the production of human therapeutic proteins in yeasts and filamentous fungi,”
[cited by applicant]
Graham, F. L., et al., “Characteristics of a human cell line transformed by DNA from human adenovirus type 5,”
[cited by applicant]
Gruber, M., et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in
[cited by applicant]
Guyer, R. L., et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors,”
[cited by applicant]
De Haas, M., et al., “Fc gamma receptors of phagocytes,”
[cited by applicant]
Hellstrom, I., et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,”
[cited by applicant]
Hellstrom, I., et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,”
[cited by applicant]
Holliger, P., et al., “‘Diabodies’: small bivalent and bispecific antibody fragments,”
[cited by applicant]
Hoogenboom, H. R., “Overview of antibody phage-display technology and its applications,”
[cited by applicant]
Hudson, P. J., and Souriau, C., “Engineered antibodies,”
[cited by applicant]
Idusogie, E. E., et al., “Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc,”
[cited by applicant]
Kabat, E. A., et al., “Sequences of Proteins of Immunological Interest,” 5th Edition, U.S. Department of Public Health and Human Services, Public Health Service, NIH publication No. 91-3242, National Institutes of Healt…
[cited by applicant]
Kanda, Y., et al., “Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC,”
[cited by applicant]
Kashmiri, S. V. S., et al., “SDR grafting—a new approach to antibody humanization,”
[cited by applicant]
Kim, J. K., et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor,”
[cited by applicant]
Klimka, A., et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,”
[cited by applicant]
Kostelny, S. A., et al., “Formation of a bispecific antibody by the use of leucine zippers,”
[cited by applicant]
Kozbor, D., et al., “A human hybrid myeloma for production of human monoclonal antibodies,”
[cited by applicant]
Lee, C. V., et al., “Bivalent antibody phage display mimics natural immunoglobulin,”
[cited by applicant]
Lee, C. V., et al., “High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold,”
[cited by applicant]
Lefranc, M. P., et al., “IMGT, the international ImMunoGeneTics database,”
[cited by applicant]
Li, H., et al., “Optimization of Humanized IgGs In Glycoengineered Pichia Pastoris,” Nature Biotechnology 24(2):210-215, Nature America Publishing, United States (Feb. 2006).
[cited by applicant]
Li, J., et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology,”
[cited by applicant]
Lonberg, N., “Fully human antibodies from transgenic mouse and phage display platforms,”
[cited by applicant]
Lonberg, N., “Human antibodies from transgenic animals,”
[cited by applicant]
Marks, J. D., and Bradbury, A., “Selection of human antibodies from phage display libraries,”
[cited by applicant]
Marks, J. D., et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,”
[cited by applicant]
Mather, J. P., “Establishment and characterization of two distinct mouse testicular epithelial cell lines,”
[cited by applicant]
Mather, J. P., et al., “Culture of testicular cells in hormone-supplemented serum-free medium,”
[cited by applicant]
Mccafferty, J., et al., “Phage antibodies: filamentous phage displaying antibody variable domains,”
[cited by applicant]
Migliorini, P., et al., “The IL-1 family cytokines and receptors in autoimmune diseases,”
[cited by applicant]
Morrison, S. L., et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,”
[cited by applicant]
Okazaki A., et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa,”
[cited by applicant]
Osbourn, J., et al., “From rodent reagents to human therapeutics using antibody guided selection,”
[cited by applicant]
Padlan, E. A., “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,”
[cited by applicant]
Petkova, S. B., et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,”
[cited by applicant]
Pluckthun, A., “Chapter 11: Antibodies from Escherichia coli,” in
[cited by applicant]
Portolano, S., et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain ‘roulette’,”
[cited by applicant]
Presta, L. G., et al., “Humanization of an antibody directed against IgE,”
[cited by applicant]
Queen, C., et al., “A humanized antibody that binds to the interleukin 2 receptor,”
[cited by applicant]
Ravetch, J. V., and Kinet, J. P., “Fc receptors,”
[cited by applicant]
Riechmann, L., et al., “Reshaping human antibodies for therapy,”
[cited by applicant]
Ripka, J., et al., “Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose,”
[cited by applicant]
Rosok, M. J., et al., “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab,”
[cited by applicant]
Shields, R. L., et al., “High resolution mapping of the binding site on human IgGI for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,”
[cited by applicant]
Sidhu, S. S., et al., “Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions,”
[cited by applicant]
Sims, M. J., et al., “A humanized CD18 antibody can block function without cell destruction,”
[cited by applicant]
Tutt, A., et al., “Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells,” Journal of Immunology 147(1):60-69, American Associa…
[cited by applicant]
UniProt, “Interleukin-1 receptor accessory protein,” Accession No. P59822, accessed at URL:[https://www.uniprot.org/uniprot/P59822] on Dec. 27, 2021, 8 pages.
[cited by applicant]
UniProt, “Interleukin-1 receptor accessory protein,” Accession No. Q9NPH3, accessed at URL:[https://www.uniprot.org/uniprot/Q9NPH3] on Dec. 27, 2021, 14 pages.
[cited by applicant]
Urlaub, G., and Chasin, L. A., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,”
[cited by applicant]
Van Dijk, M. A., and Van De Winkel, J. G., “Human antibodies as next generation therapeutics,”
[cited by applicant]
Vollmers, H. P., and Brandlein, S., “Death by stress: natural IgM-induced apoptosis,”
[cited by applicant]
Vollmers H. P., and Brandlein, S., “The ‘early birds’: natural IgM antibodies and immune surveillance,”
[cited by applicant]
Wright, A., and Morrison, S. L., “Effect of glycosylation on antibody function: implications for genetic engineering,”
[cited by applicant]
Yamane-Ohnuki, N., et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity,”
[cited by applicant]
Yazaki, P. J., and Wu, A. M., “Chapter 15: Expression of Recombinant Antibodies in Mammalian Cell Lines,” in Methods in Molecular Biology 248, pp. 255-268, Lo, B. K. C., ed., Humana Press, United States (2003).
[cited by applicant]
Zapata, G., et al., “Engineering linear F(ab′)2 fragments for efficient production in
[cited by applicant]
Zola, H., “Chapter 6—Using Monoclonal Antibodies: Soluble Antigens,” in
[cited by applicant]
Cacia, J., et al., “Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity,” Biochemistry 35(6):1897-19…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/075235, mailed Mar. 1, 2022, European Patent Office, Netherlands, 20 pages.
[cited by applicant]
Lo, M., et al., “Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice,” J. Biol. Chem. 292(9):3900-3908, Elsevier, Netherlands (2017).
[cited by applicant]
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. 79(6):1979-1983, National Academy of Sciences, United States (1982).
[cited by applicant]
Heppner, G.H., and Miler, B.E., “Tumor heterogeneity: biological implications and therapeutic consequences,” Cancer Metastasis Rev 2(1):5-23, Springer Netherlands, Netherlands (1983).
[cited by applicant]
Wang, D., et al., “Structural insights into the assembly and activation of IL-1β with its receptors,” Nat Immunol 11(10):905-911, Nature Publishing Group, United Kingdom (Oct. 2010).
[cited by applicant]
Definition of Disease, Merriam-Webster.com, 1 page (2023).
[cited by applicant]
Mainehealth, “Orthopedic Surgery,” accessed at https://www.mainehealth.org/Services/Orthopedics-Sports-Medicine/Orthopedic-Surgery, accessed on Feb. 16, 2023, 3 pages.
[cited by applicant]
Lazar, E., et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,” Mol Cell Biol 8(3):1247-1252, Taylor and Francis Inc., United States (Mar. 1…
[cited by applicant]
Bowie, J.U., et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science 247(4948):1306-1310, American Association for the Advancement of Science, United States (Mar. 1990).
[cited by applicant]
Burgess, W.H., et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a…
[cited by applicant]
Jain, R.K., “Barriers to drug delivery in solid tumors,” Sci Am 271(1):58-65, American Association for the Advancement of Science, United States (Jul. 1994).
[cited by applicant]
Maccallum, R.M., et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J Mol Biol 262(5):732-745, American Society for Biochemistry and Molecular Biology Inc., United States (Oct. 1996).
[cited by applicant]
Gura, T., “Antibody-antigen interactions: contact analysis and binding site topography,” Science 278(5340):1041-1042, American Association for the Advancement of Science, United States (Nov. 1997).
[cited by applicant]
Greenspan, N.S., and Di Cera, E., “Defining epitopes: It's not as easy as it seems,” Nat Biotechnol 17(10):936-937, Nature Publishing Group, United Kingdom (Oct. 1999).
[cited by applicant]
Bork, P., “Powers and pitfalls in sequence analysis: the 70% hurdle,” Genome Res 10(4):398-400, Cold Spring Harbor Laboratory Press, United States (Apr. 2000).
[cited by applicant]
Sporn, M.B., and Suh, N., “Chemoprevention of cancer,” Carcinogenesis 21(3):525-530, Oxford University Press, United Kingdom (Mar. 2000).
[cited by applicant]
Auerbach, R., et al., “Angiogenesis assays: problems and pitfalls,” Cancer Metastasis Rev 19(1-2):167-172, Springer Netherlands, Netherlands (2000).
[cited by applicant]
Vajdos, F.F., et al., “Angiogenesis assays: problems and pitfalls,” J Mol Biol 320(2):415-428, Academic Press, United States (Jul. 2002).
[cited by applicant]
Paul, et al., Fundamental Immunology, 5
[cited by applicant]
Casset, F., et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem Biophys Res Commun 307(1):198-205, Elsevier B.V., United States (Jul. 2003).
[cited by applicant]
Hait, W.N., “Anticancer drug development: the grand challenges,” Nat Rev Drug Discov 9(4):253-254, Nature Publishing Group, United Kingdom (Apr. 2010).
[cited by applicant]
Sela-Culang, I., et al., “The structural basis of antibody-antigen recognition,” Front Immunol 4:302, Frontiers Media SA, Switzerland (Oct. 2013).
[cited by applicant]
Gravanis, I., et al., “The changing world of cancer drug development: the regulatory bodies' perspective,” Chin Clin Oncol 3(2):22, AME Publishing Company, Hong Kong (Jun. 2014).
[cited by applicant]
Beans, C., “News Feature: Targeting metastasis to halt cancer's spread,” Proc Natl Acad Sci USA 115(50):12539-12543, National Academy of Sciences, United States (Dec. 2018).
[cited by applicant]